Literature DB >> 12591679

Transcatheter arterial chemoembolization of hepatocellular carcinoma: usefulness of coded phase-inversion harmonic sonography.

Yasunori Minami1, Masatoshi Kudo, Toshihiko Kawasaki, Masayuki Kitano, Hobyung Chung, Kiyoshi Maekawa, Hitoshi Shiozaki.   

Abstract

OBJECTIVE: The purpose of our study was to assess the value of coded phase-inversion harmonic sonography performed approximately 1 week after the patients had undergone transcatheter arterial chemoembolization with iodized oil for hepatocellular carcinoma. SUBJECTS AND METHODS: We studied 40 patients with 44 nodules measuring 1.5-11.0 cm in diameter (mean +/- SD, 3.9 +/- 2.0 cm) who underwent transcatheter arterial chemoembolization. Coded phase-inversion harmonic sonography, a technique based on a combination of phase-inversion harmonics and coded technology, was performed with a contrast agent approximately 1 week after chemoembolization. The results were compared with those obtained using dynamic CT (n = 44 lesions) and dynamic MR imaging (n = 20 lesions). We also evaluated the recurrence of hepatocellular carcinoma during clinical follow-up in 17 patients who did not undergo additional local therapy.
RESULTS: The detection rates of intratumoral vascularity of coded phase-inversion harmonic sonography, dynamic CT, and dynamic MR imaging were, respectively, 38 (86%) of 44 lesions, 19 (43%) of 44 lesions, and 10 (50%) of 20 lesions. Of 19 nodules of hepatocellular carcinoma treated only by transcatheter arterial chemoembolization, 17 nodules showed enhancement on coded phase-inversion harmonic sonography, suggesting incomplete responses. In all 17 nodules, apparent recurrence was noted on dynamic CT during clinical follow-up, even in nodules that had been observed to be completely filled with iodized oil 1 week after the chemoembolization.
CONCLUSION: We found coded phase-inversion harmonic sonography to be highly sensitive and accurate for evaluating the treatment response in patients with hepatocellular carcinoma even shortly after treatment. Consequently, it allows early recognition of the need for additional local ablation therapy and estimation of the risk of hepatocellular carcinoma recurrence.

Entities:  

Mesh:

Year:  2003        PMID: 12591679     DOI: 10.2214/ajr.180.3.1800703

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  24 in total

Review 1.  Recent applications of ultrasound: diagnosis and treatment of hepatocellular carcinoma.

Authors:  Hitoshi Maruyama; Masaaki Ebara
Journal:  Int J Clin Oncol       Date:  2006-08       Impact factor: 3.402

2.  Usefulness of Sonazoid contrast-enhanced ultrasonography for hepatocellular carcinoma: comparison with pathological diagnosis and superparamagnetic iron oxide magnetic resonance images.

Authors:  Keiko Korenaga; Masaaki Korenaga; Matakazu Furukawa; Takahiro Yamasaki; Isao Sakaida
Journal:  J Gastroenterol       Date:  2009-04-23       Impact factor: 7.527

3.  Evaluation of transcatheter arterial embolization therapy on hepatocellular carcinomas using contrast-enhanced harmonic power Doppler sonography: comparison with CT, power Doppler sonography, and dynamic MRI.

Authors:  Toshihide Shima; Masayuki Mizuno; Hideaki Otsuji; Chiemi Mizuno; Hirozumi Obata; Hyohun Park; Shinobu Nakajo; Takeshi Okanoue
Journal:  J Med Ultrason (2001)       Date:  2005-09       Impact factor: 1.314

4.  Quantification of tumor vascularity with contrast-enhanced ultrasound for early response of transcatheter arterial chemoembolization for hepatocellular carcinoma: a report of three cases.

Authors:  Yasunori Minami; Naoya Okumura; Norio Yamamoto; Naoko Tsuji; Yuko Kono; Masatoshi Kudo
Journal:  J Med Ultrason (2001)       Date:  2011-10-29       Impact factor: 1.314

5.  Defect Reperfusion Imaging with Sonazoid®: A Breakthrough in Hepatocellular Carcinoma.

Authors:  M Kudo
Journal:  Liver Cancer       Date:  2015-12-15       Impact factor: 11.740

6.  Preliminary study of contrast-enhanced harmonic endosonography with second-generation contrast agents.

Authors:  Masayuki Kitano; Masatoshi Kudo; Hiroki Sakamoto; Tatsuya Nakatani; Kiyoshi Maekawa; Nobuyuki Mizuguchi; Yasuhiro Ito; Motohiro Miki; Uwe Matsui; Tammo von Schrenck
Journal:  J Med Ultrason (2001)       Date:  2008-03-15       Impact factor: 1.314

7.  Radiofrequency ablation of hepatocellular carcinoma: Current status.

Authors:  Yasunori Minami; Masatoshi Kudo
Journal:  World J Radiol       Date:  2010-11-28

Review 8.  Imaging Modalities for Assessment of Treatment Response to Nonsurgical Hepatocellular Carcinoma Therapy: Contrast-Enhanced US, CT, and MRI.

Authors:  Yasunori Minami; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2015-04-08       Impact factor: 11.740

Review 9.  Current role of ultrasound for the management of hepatocellular carcinoma.

Authors:  Hitoshi Maruyama; Masaharu Yoshikawa; Osamu Yokosuka
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

10.  Dynamic imaging of pancreatic diseases by contrast enhanced coded phase inversion harmonic ultrasonography.

Authors:  M Kitano; M Kudo; K Maekawa; Y Suetomi; H Sakamoto; N Fukuta; R Nakaoka; T Kawasaki
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.